A compound of general formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof RXY-ONO2 (I) in which R is the prostaglandin residue of formula (II): ** Formula ** in which the symbol - - represents a single bond L is: ** Formula ** X is -O- or -S； Y is a bivalent radical having the following meaning: a) - linear or branched C1-C20 alkylene, being optionally substituted with one or more of the substituents selected from the group consisting of: halogen, hydroxy, -ONO2 or T atoms , wherein T is -OC (O) (C1-C10 alkyl) -ONO2 or -O (C1-C10 alkyl) -ONO2； - cycloalkylene with 5 to 7 carbon atoms in the cycloalkylene ring, the ring being optionally substituted with side chains T1, wherein T1 is linear or branched C1-C10 alkyl； b) ** Formula ** c) ** Formula ** in which n is an integer from 0 to 20 and n1 is an integer from 1 to 20； d) ** Formula ** in which X1>； = -OCO- or -COO- and R2 is H or CH3； Z is - (CH) n 1- or the bivalent radical defined above in b) n1 is as defined above and n2 is an integer from 0 to 2； e) ** Formula ** in which: Y1 is -CH2-CH2- (CH2) n 2-； or -CH>； = CH- (CH2) n 2-； Z is - (CH) n 1- or the bivalent radical defined above in b) n1, n2, R2 and X1 are as defined above； f) ** Formula ** in which: n1 and R2 are as defined above, R3 is H or -COCH3； provided that when Y is selected from the bivalent radicals mentioned in b) -f), the terminal group -ONO2 is attached to - (CH2) n 1； g) ** Formula ** in which X2 is -O- or -S-, n3 is an integer from 1 to 6 and R2 is as defined above； h) ** Formula ** in which: n4 is an integer from 0 to 10； n5 is an integer from 1 to 10； R4, R5, R6, R7 are the same or different, and are H or linear or branched C1-C4 alkyl； in which the group -ONO2 is linked to ** Formula ** in which n5 is as defined above； Y2 is a saturated, unsaturated or aromatic 5 or 6-membered heterocyclic ring, which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur, and is selected from ** Formula **Un compue
